SRT 1720 Hydrochloride 是选择性的和具有口服活性的 SIRT1 激活剂，EC₅₀为 0.10 μM，对 SIRT2 和 SIRT3 的作用较弱。

SRT 1720 Hydrochloride is a selective and orally active activator of SIRT1 with an EC 50 of 0.10 μM, and shows less potent activities on SIRT2 and SIRT3.

Solid

SIRT1 0.10 μM (EC50) SIRT1 0.16 μM (EC1.5)

SRT 1720 effectively decreases the acetylation of p53 in cells even in the absence of SIRT1, and this is attributed to inhibition of histone acetyltransferase p300. has not independently confirmed the accuracy of these methods. They are for reference only.

SRT 1720 (10, 30, 100 mg/kg, p.o.) treatment significantly reduces fasting blood glucose to near normal levels in Lep mice.
SRT 1720 has ability to protect against the negative effects of diet-induced obesity in mice, and has a connection to metabolic adaptation in fatty acid and oxidative metabolism through downstream targets of SIRT1 such as PGC1α and FOXO1.
SRT 1720 (50-100 mg/kg, p.o.), during emphysema development attenuates elastase-induced airspace enlargement and lung function impairment as well as reduces arterial oxygen saturation in WT mice. has not independently confirmed the accuracy of these methods. They are for reference only.

Room temperature in continental US; may vary elsewhere.

4°C, stored under nitrogen In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)

[1]. Milne JC et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007 Nov 29;450(7170):712-6
[2]. Baur JA, et al. Are sirtuins viable targets for improving healthspan and lifespan?,Nat Rev Drug Discov. 2012 Jun 1;11(6):443-61
[3]. Yao H, et al. SIRT1 protects agai

In Vitro: DMSO : 62.5 mg/mL (123.51 mM; Need ultrasonic)H₂O : 15.7 mg/mL (31.03 mM; Need ultrasonic and warming)配制储备液